The evaluation of the effectiveness of mesotherapy with piroxicam versus acupuncture in Reducing Pain and Improving Function in Patients with Non-Specific Neck Pain(Randomized controlled trial)

Start Date22 Sep 2024

Sponsor / Collaborator

Shiraz University of Medical Sciences

IRCT20180526039839N1 / CompletedPhase 2/3

Clinical trial of a topical emulgel containing piroxicam-entrapped nanoniosomes in patients with osteoarthritis or rheumatoid arthritis complaining joint pain

Start Date20 Feb 2024

Sponsor / Collaborator-

IRCT20230202057310N4 / RecruitingPhase 1/2IIT

Comparative Analysis of Piroxicam and Post-isometric Exercises in Improving Knee Osteoarthritis

Start Date12 Sep 2023

Sponsor / Collaborator-

100 Clinical Results associated with Piroxicam

100 Translational Medicine associated with Piroxicam

100 Patents (Medical) associated with Piroxicam

3,120

Literatures (Medical) associated with Piroxicam

01 Oct 2024·INTERNATIONAL DENTAL JOURNAL

Acute Pain Management Following Mandibular Third Molar Exodontia: A Bibliometric Analysis of Randomized Controlled Trials

Article

Author: Li, Duoduo ; Han, Sheng ; Xu, He ; Cai, Zhigang ; Zhu, He ; Li, Nan ; Huang, Jinwei ; Gan, Yena

INTRODUCTION AND AIMS:

To reveal the evolution of pain management strategies following mandibular third molar (M3M) exodontia, examine the geographic contribution of research, and explore future developments through a bibliometric analysis.

METHODS:

A comprehensive search was conducted in various leading databases. Data on bibliometrics, participant demographics, and agent regimens were extracted for eligible studies. Descriptive bibliometrics, citation analysis, and keyword bursts were performed to assess the research outputs, distribution, and emerging hotspots.

RESULTS:

A total of 173 randomized control trials from 2004 to 2024 were included. The number of publications showed a consistent upward trend since 2007. Brazil exhibited the most publications and citations. Germany presented the highest mean citations per publication. Brazil, Spain, and Italy showed the closest collaboration. Appropriately 14,391participants with 14,710 extracted M3M were enrolled. Nonsteroidal anti-inflammatory drugs (NSAIDs) were the most extensively studied analgesics, followed by glucocorticoids, opioids, and paracetamol. NSAIDs and paracetamol were predominantly administered orally, whereas glucocorticoids and opioids were primarily applied topically (P < .001). Studies on opioids significantly predated the studies using other agents. Adverse events were found in 50.87% of the included studies, where nausea and vomiting were the most frequently reported. Tramadol and piroxicam have drawn increasing interest in recent years.

CONCLUSIONS:

This study revealed information on the research outputs, distribution, and future developments of analgesic agents following M3M exodontia. Brazil exhibited the highest level of productivity and recorded the most citations. NSAIDs generated the largest amount of research and are emerging as a benchmark for comparative studies. Oral administration is the most frequently used approach for agent delivery. Nausea and vomiting are the most commonly reported adverse effects.

CLINICAL RELEVANCE:

The bibliometric analysis offers insights into the field of pain management following mandibular 3rd molar exodontia and how it has evolved. Tramadol and piroxicam have become research hotspots in recent years.

01 Oct 2024·INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

Identifying alkaline phosphatase inhibitory potential of cyclooxygenase-2 inhibitors: Insights from molecular docking, MD simulations, molecular expression analysis in MCF-7 breast cancer cell line and in vitro investigations

Article

Author: Hussain, Safdar ; Putra, Purnawan Pontana ; Ashraf, Muhammad ; Hamid, Sujhla ; Iqbal, Ambar

Alkaline phosphatases (APs, EC 3.1.3.1) belong to a superfamily of biological macromolecules that dephosphorylate many phosphometabolites and phosphoproteins and their overexpression is intricated in the spread of cancer to liver and bones, neuronal disorders including Alzheimer's disease (AD), inflammation and others. It was hypothesized that cyclooxygenase-2 (COX-2) selective inhibitors may possess anti-APs potential and may be involved in anticancer proceedings. Three COX-2 inhibitors including nimesulide, piroxicam and lornoxicam were evaluated for the inhibition of APs using in silico and in vitro methods. Molecular docking studies against tissue nonspecific alkaline phosphatase (TNAP) offered the best binding affinities for nimesulide (-11.14 kcal/mol) supported with conventional hydrogen bonding and hydrophobic interactions. MD simulations against TNAP for 200 ns and principal component analysis (PCA) reiterated the stability of ligand-receptor complexes. Molecular expression analysis of TNAP enzyme in the breast cancer cell line MCF-7 exhibited 0.24-fold downregulation with 5 μM nimesulide as compared with 0.26-fold standard 10 μM levamisole. In vitro assays against human placental AP (hPAP) displayed potent inhibitions of these drugs with IC₅₀ values of 0.52 ± 0.02 μM to 3.46 ± 0.13 μM and similar results were obtained for bovine intestinal AP (bIAP). The data when generalized collectively emphasizes that the inhibition of APs by COX-2 inhibitors provides another target to work on the development of anticancer drugs.

23 Sep 2024·PHYTOCHEMICAL ANALYSIS

UPLC-MS/MS and chemometrics analyses reveal chemical profile and anti-inflammatory activity of Bienertia cycloptera Bunge fractions.

Article

Author: Mahmoud, Fatma A A ; Ghareeb, Doaa A ; Shawky, Eman ; El-Gazzar, Nahla S ; Selim, Dina A

INTRODUCTION:

Bienertia cycloptera is a species belonging to the Chenopodiaceae family. According to earlier reports, a unique research study on the phytochemistry and biological analysis of that species was conducted.

OBJECTIVE:

This study presents an integrated metabolomics investigation combined with multivariate analysis of various extractive fractions of B. cycloptera aerial parts. This study is the first attempt to explore the anti-inflammatory metabolites from B. cycloptera, showing its significance as a valuable traditional medicine.

METHODOLOGY:

By comparing retention times, quasi-molecular ions, and MS/MS fragment ions with databases and literature references, metabolite annotation was accomplished using ultra performance liquid chromatography (UPLC)/triple quadrupole mass spectrometry (MS). Moreover, the effects of the studied samples on the gene expression of the four pro-inflammatory cytokines (IL-1β, IL-6, TNF-α, and INF-γ) using polymerase chain reaction (PCR) and comparing their results by those caused by piroxicam were tested to determine their anti-inflammatory efficacy.

RESULTS:

Chemical profiling revealed diverse metabolites, with 62 chromatographic peaks identified across various chemical classes. UPLC-MS/MS of different B. cycloptera fractions unveiled distinct chemical profiles. Results showed distinct chemical compositions in each fraction, with petroleum ether fraction enriched in sterols and fatty acids; methylene chloride fraction in alkaloids, sterols, and cardenolides; ethyl acetate fraction in alkaloids, flavonoids, cardenolides, and phenolic acids; and n-butanol fraction in flavonoids, alkaloids, and phenolic acids. Multivariate data analysis illustrated clustering patterns among petroleum ether, methylene chloride, ethyl acetate, and n-butanol fractions. OPLS-DA models were constructed to discern inter-class differences, identifying discriminatory metabolites. In vitro cytotoxicity and anti-inflammatory assays demonstrated the safety and efficacy of B. cycloptera fractions, with significant downregulation of pro-inflammatory markers. Further analysis revealed specific metabolites associated with anti-inflammatory effects, such as p-hydroxybenzoic acid, vanillic acid, tachioside, ferulic acid, staphylionoside D, humilixanthin, bergaptol, vulgaxanthin I, and portulacaxanthin III.

CONCLUSION:

The findings of this study provide valuable insights into the chemical composition and bioactivity of B. cycloptera fractions, suggesting their potential as therapeutic agents and warranting further investigation.

News (Medical) associated with Piroxicam

20 Oct 2023

·www.sciencedaily.com

Morning-after pill more effective when taken with an anti-inflammatory painkiller, researchers find

A research team recently published findings on adding an anti-inflammatory painkiller used for arthritis pain to an oral emergency contraceptive pill (also known as the morning-after pill) to increase the effectiveness of pregnancy prevention. A collaborative research team, including members of LKS Faculty of Medicine of the University of Hong Kong (HKUMed), as well as The Family Planning Association of Hong Kong (FPAHK) and Sweden's Karolinska Institutet, recently published its findings on adding an anti-inflammatory painkiller used for arthritis pain to an oral emergency contraceptive pill (also known as the morning-after pill) to increase the effectiveness of pregnancy prevention. The study was published in a recent issue of The Lancet. Background Emergency contraception is a contraceptive method that can be used to prevent an unintended pregnancy when a regular contraceptive method fails or is not used. It can be in the form of an oral emergency contraceptive pill or the insertion of a copper intrauterine contraceptive device (Cu-IUD). The oral levonorgestrel emergency contraceptive pill is one of the most popular choices of emergency contraception and is widely used in most countries. It was pioneered by a clinical trial in Hong Kong led by HKUMed's Professor Ho Pak-chung, published in 1993. However, all contraceptive methods have a failure rate. Hence, the research team is continuing its efforts to explore more effective options. Prostaglandins are substances produced by most body tissues in humans and mediate a number of biological processes, including inflammatory responses. In the reproductive system, prostaglandin is an important mediator of processes like ovulation, fertilisation and embryo implantation. The research team postulated that adding a medication that blocks prostaglandin synthesis may have an additional complementary effect in achieving contraception. Research methods and findings The research team conducted the first randomised, placebo-controlled trial in the world on the use of piroxicam, a long-acting nonsteroidal anti-inflammatory drug (NSAID) used to treat arthritis pain, which blocks prostaglandin production in the body, in combination with the levonorgestrel emergency contraceptive pill. The findings revealed that with the new combination regimen, only one out of 418 women became pregnant, while seven out of another 418 women receiving levonorgestrel and a placebo became pregnant. The results showed that the percentage of pregnancies prevented by piroxicam-levonorgestrel co-treatment (94.7%) was significantly higher than that of the levonorgestrel emergency contraceptive pill alone (63.4%). There was no significant difference in the occurrence of adverse effects, including changes to the menstrual bleeding pattern and stomach ache following intake of the two regimens. Significance of the study Chief-investigator Dr Raymond Li Hang-wun, from HKUMed, said, 'Our study is the first to find that piroxicam, a readily available medication, taken at the same time as the levonorgestrel pill can prevent more pregnancies than levonorgestrel alone. We hope these findings will lead to further research and ultimately changes in clinical guidelines to enable women around the world to access more effective emergency contraception.' Co-investigator Dr Sue Lo Seen-tsing, from FPAHK, said, 'The levonorgestrel pill was registered in Hong Kong in 2002 and has been used safely since then. Locally, emergency contraceptives must be prescribed by healthcare providers, who assess which emergency contraceptive method is the most suitable in each case. Contraceptive counselling should be provided to help women seeking emergency contraception understand that it cannot replace regular contraceptives and to motivate them to use the latter. Since there is still a small failure rate, a follow-up visit is important. The levonorgestrel emergency contraception pill should be taken within 72 hours after unprotected sex; the earlier it is taken, the more effective it is.' About the research team The study was led by Dr Raymond Li Hang-wun, Clinical Associate Professor in the Department of Obstetrics and Gynaecology, School of Clinical Medicine, HKUMed. The collaborative research team also included Professor Ho Pak-chung, Emeritus Professor, and Professor Ernest Ng Hung-yu, Clinical Professor, Department of Obstetrics and Gynaecology, School of Clinical Medicine, HKUMed; Carol Fong Ho-yi, Department of Medicine, School of Clinical Medicine, HKUMed; Dr Sue Lo Seen-tsing, The Family Planning Association of Hong Kong; and Professor Kristina Gemzell-Danielsson, Head, Department of Women's and Children's Health, Karolinska Institutet, Sweden. Acknowledgements This work was supported by research funding from the Department of Obstetrics and Gynaecology, School of Clinical Medicine, HKUMed.

Clinical ResultDrug Approval

24 Jan 2021

·www.biospace.com

Nanoform's Clinical Study Indicates Positive Interim Results - Jan 22, 2021

HELSINKI, Jan. 22, 2021 /PRNewswire/ -- Nanoform Finland Plc ("Nanoform"), an innovative nanoparticle medicine enabling company, today announced positive interim results from its clinical study. The faster absorption data implies that small particles can indeed be powerful. Nanoform has received interim study results related to its Phase 1, Single-Centre, Part Crossover, Open-Label, Partially-Randomised Study Designed to Evaluate the Pharmacokinetic (PK) Profile of Piroxicam following Administration of Nanoformed Oral Immediate Release (IR) Piroxicam Tablet and an IR Reference Product in Healthy Subjects (UNICORN). These interim results are based on the first cohort of twelve healthy volunteers dosed in December 2020 at Quotient Sciences' facilities in Nottingham, UK. Final results of the study are expected before the end of Q2 2021, as previously announced. This first set of human data supports Nanoform's value proposition that nanoparticles can enable faster dissolution rate, more rapid absorption, improve drug delivery performance, and ultimately generate patient benefit. The interim results obtained from the ongoing clinical trial, suggest that a 20 mg nanoformed oral piroxicam tablet achieved significantly faster absorption when compared to a 20 mg reference oral piroxicam tablet (Felden®) from the originator Pfizer. The time of maximum plasma concentration (T max ) was obtained earlier than with the reference product. These interim results support the further development of fast-acting forms of poorly soluble drugs by using the CESS® nanoforming technology. For further information, please contact: Prof. Edward Hæggström, CEO edward.haeggstrom@nanoform.com +358 29 370 0150 For investor relations queries, please contact: Henri von Haartman, Director of Investor Relations hvh@nanoform.com +46 7686 650 11 The information in the press release is information that Nanoform is obliged to make public pursuant to the EU Market Abuse Regulation. The information was sent for publication, through the agency of the contact persons set out above, on January 22nd, 2021 at 08:10 a.m. Finnish time. About Nanoform Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to provide hope for patients in developing new and improved medicines utilizing Nanoform's platform technologies. The Company focuses on reducing attrition in clinical trials and on enhancing drug molecules' formulation performance through its nanoforming services. Nanoform's capabilities span the small to large molecule development space and the company focuses on solving key issues in drug solubility and bioavailability and on enabling novel drug delivery applications. Nanoform's shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: Danske Bank A/S, Finland Branch, +358 40 562 1806. For more information please visit Forward-Looking Statements This press release contains forward-looking statements, including, without limitation, statements regarding Nanoform's strategy, business plans and focus. The words may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, any related to Nanoform's business, operations, clinical trials, supply chain, strategy, goals and anticipated timelines, competition from other companies, and other risks specified in Nanoform's prospectus published (on May 22, 2020) in connection with Nanoform's initial public offering (the "Prospectus") under "Risk Factors" and in our other filings or documents furnished to the Finnish Financial Supervisory Authority in connection with the Prospectus. Nanoform cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Nanoform disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent Nanoform's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. This information was brought to you by Cision The following files are available for download: View original content: SOURCE Nanoform

Financial StatementIPO

100 Deals associated with Piroxicam

External Link

KEGG	Wiki	ATC	Drug Bank
D00127	Piroxicam	M02AA07 M01AC01 S01BC06	DB00554

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Bursitis	JP	FUJIFILM Toyama Chemical Co., Ltd.	28 Feb 2007
Myalgia	JP	Pfizer Japan, Inc.	25 Sep 1986
Periarthritis scapulohumeralis	JP	Pfizer Japan, Inc.	25 Sep 1986
Tennis Elbow	JP	Pfizer Japan, Inc.	25 Sep 1986
Tenosynovitis	JP	Pfizer Japan, Inc.	25 Sep 1986
Osteoarthritis	US	Pfizer Laboratories (Pty) Ltd.	06 Apr 1982
Rheumatoid Arthritis	US	Pfizer Laboratories (Pty) Ltd.	06 Apr 1982
Pain	CN	Jiangsu Yixing Qianjin Pharmacy Factory	01 Jan 1982

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03614494 (CTgov)	Phase 2/3	Contraception	860	Levonorgestrel 1.5mg+Piroxicam 40 mg (Piroxicam)	ftvcufirec(ndmtzomjxw) = mhpmkbwnyz leyjwjlfrz (equnzjdfce, tvgvwlyaxn - mxgxnefadb) View more	-	06 May 2024
				Levonorgestrel 1.5mg (Placebo)	ftvcufirec(ndmtzomjxw) = czvcftqssx leyjwjlfrz (equnzjdfce, pdpxvvwvnb - ksxdtzcamh) View more
EULAR2022	Not Applicable	Non-radiographic axial spondyloarthritis	43	Continuous NSAIDs intake	ecfigryvfp(heuwgvyajk) = wpdaghaxtq kmdjlcenzi (zcsoympluv ) View more	Positive	01 Jun 2022
				Occasional NSAIDs intake	enoizkmybj(woyumkeefw) = yjzsewadmr fmiajfxyaf (cqadpvuvxp )
NCT02450487 (CTgov)	Phase 4	Pain \| Cytochrome p450 enzyme deficiency	105	Piroxicam	plkxijjged(tjmgdfiivh) = wckjuqfsxy zhqgmxdabj (wfggiqdssc, puyrctxodl - fjeaabqzgy) View more	-	16 Sep 2020
ISRCTN22070974 (Pubmed \| Curr Med Res Opin)	Phase 3	Actinic Keratosis	54	ACTX	azvozgiuko(zbhwhpuxpo) = exjtlwthfe oldsczwvnq (csfdtordla ) View more	-	01 Oct 2019
EULAR2008	Not Applicable	-	-	Ibuprofen	xjxeucpoeg(agjcwgwgfx) = mmavwdyxof lydfjpkjut (iqxhusgrca )	-	11 Jun 2008
				Naproxen	xjxeucpoeg(agjcwgwgfx) = tyyipchnot lydfjpkjut (iqxhusgrca )
EULAR2001	Not Applicable	-	70	Tramadol/piroxicam combination	bzwopevgmc(lmmkffbgvv) = 18% rpvtolrwuj (gxnexbyhqh ) View more	-	13 Jun 2001
Pubmed	Not Applicable	Periarthritis scapulohumeralis \| Cervicobrachial syndrome	-	Piroxicam	abngtdxkuu(pzrwuvbsqt) = Fewer adverse reactions were observed with piroxicam paidfznoxw (ksgoklbtbg ) View more	-	01 Jan 1983
				Indomethacin

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis